Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.

Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.

S100A11 is a calcium-binding protein implicated in a variety of biologic functions such as proliferation and differentiation as well as in cancer. To further understand its role in prostate cancer, we performed immunohistochemistry on a series of benign, premalignant, malignant and metastatic prosta...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Rehman, I, Azzouzi, A, Cross, S, Deloulme, J, Catto, J, Wylde, N, Larre, S, Champigneuille, J, Hamdy, F
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	2004

Míreanna comhchosúla

Calgizzarin (S100A11) immunostaining pattern is altered in prostate cancer suggesting a role in tumourigenesis
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2003)

S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors.
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2004)

Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers.
de réir: Cross, S, et al.
Foilsithe / Cruthaithe: (2005)

S100A11 protein is overexpressed in common human cancers with spatial translocation from the nucleus to cytoplasm
de réir: Cross, S, et al.
Foilsithe / Cruthaithe: (2004)

Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis
de réir: Lucie Andrés Cerezo, et al.
Foilsithe / Cruthaithe: (2017-04-01)

Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer.
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2005)

S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils
de réir: Adéla Navrátilová, et al.
Foilsithe / Cruthaithe: (2021-03-01)

Clinically localised prostate cancer is microsatellite stable.
de réir: Azzouzi, A, et al.
Foilsithe / Cruthaithe: (2007)

Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2004)

DNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer.
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2007)

Tissue microarray immunohistochemistry and cluster analysis confirms the validity of candidate proteins in prostate cancer identified by proteomic analysis of urine
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2005)

Proteomic analysis of voided urine following prostatic massage reveals tumour specific alterations
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2004)

Prostate cancer proteomics: The urgent need for clinically validated biomarkers
de réir: Evans, C, et al.
Foilsithe / Cruthaithe: (2009)

The use of proteomics in urological research
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2005)

Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer.
de réir: Leiblich, A, et al.
Foilsithe / Cruthaithe: (2006)

Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer
de réir: Catto, J, et al.
Foilsithe / Cruthaithe: (2006)

Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A.
de réir: Leiblich, A, et al.
Foilsithe / Cruthaithe: (2007)

Gli1 appears to be constitutively expressed in the lumenal epithelial cells of the prostate but not in the basal cell layer or the mesenchyme
de réir: Spencer, A, et al.
Foilsithe / Cruthaithe: (2004)

S100A9 protein is overexpressed in human breast and squamous cell cancers
de réir: Cross, S, et al.
Foilsithe / Cruthaithe: (2004)

Three dimensional ultrasound and prostate cancer.
de réir: Mehta, S, et al.
Foilsithe / Cruthaithe: (2004)

Itraq-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2008)

iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression.
de réir: Glen, A, et al.
Foilsithe / Cruthaithe: (2008)

Loss of intercellular expression of beta-dystroglycan is a common event in prostate cancer and is significantly associated with loss of differentiation
de réir: Cross, S, et al.
Foilsithe / Cruthaithe: (2005)

Proteomics and immunohistochemistry identify loss of nucleophosmin (B23) expression in bladder transitional cell carcinomas
de réir: Ahmad, M, et al.
Foilsithe / Cruthaithe: (2003)

PROLIFERATIVE INFLAMMATORY ATROPHY: POTENTIAL PRECURSOR LESION FOR PROSTATIC ADENOCARCINOMA
de réir: Benedetti-Padrón Inés, et al.
Foilsithe / Cruthaithe: (2014-01-01)

The expression of S100A6 protein in human tissues and common tumours outside the central nervous system
de réir: Cross, S, et al.
Foilsithe / Cruthaithe: (2004)

S100A8 protein is expressed in neutrophils, macrophages, some breast cancers and some squamous cell cancers
de réir: Cross, S, et al.
Foilsithe / Cruthaithe: (2004)

Tissue microarray immunohistochemistry for S100A2, S100A4, S100A6, S100A8, S100A9, S100B and annexin I with unsupervised cluster analysis produces a useful classification of oesophageal cancers
de réir: Clarke, L, et al.
Foilsithe / Cruthaithe: (2005)

There is loss of expression of S100A8 and S100A9 in oesophageal squamous carcinoma
de réir: Clarke, L, et al.
Foilsithe / Cruthaithe: (2005)

Behavior of urothelial carcinoma with respect to anatomical location.
de réir: Catto, J, et al.
Foilsithe / Cruthaithe: (2007)

Distinct patterns of microsatellite instability are seen in tumours of the urinary tract.
de réir: Catto, J, et al.
Foilsithe / Cruthaithe: (2003)

Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
de réir: Catto, J, et al.
Foilsithe / Cruthaithe: (2005)

Expression of S100A2, S100A4, S100A6 and S100A7 in oesophageal cancers follows the pattern of expression in the tissues from which they are derived and does not show any significant association with any other clinicopathological parameters
de réir: Clarke, L, et al.
Foilsithe / Cruthaithe: (2005)

Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
de réir: Catto, J, et al.
Foilsithe / Cruthaithe: (2009)

Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls.
de réir: Yates, DR, et al.
Foilsithe / Cruthaithe: (2006)

A gene promoter hypermethylation panel to detect transitional cell carcinoma of the bladder
de réir: Yates, DR, et al.
Foilsithe / Cruthaithe: (2006)

Comparing gene promoter methylation frequencies in urine from patients with bladder cancer with urine from non-cancerous young and elderly control patients
de réir: Yates, DR, et al.
Foilsithe / Cruthaithe: (2005)

FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
de réir: van Oers, J, et al.
Foilsithe / Cruthaithe: (2009)

DNA promoter methylation in urothelial cancer: a feature of the invasive phenotype and a novel therapeutic target
de réir: Catto, J, et al.
Foilsithe / Cruthaithe: (2006)

The impact of dysregulation SUMOylation on prostate cancer
de réir: Kailang Li, et al.
Foilsithe / Cruthaithe: (2025-03-01)